|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||8.32 - 13.23|
|52-week range||0.25 - 18.77|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||04 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.88|
What happened Shares of Ocugen (NASDAQ: OCGN) were skyrocketing 22.1% higher as of 11:28 a.m. EDT on Tuesday. The big jump came as investors anxiously awaited a meeting today of the World Health Organization's technical advisory committee.
The most recent examples are the explosive upward moves by shares of Donald Trump's social media-associated stocks, Digital World Acquisition (NASDAQ: DWAC) and Phunware (NASDAQ: PHUN). Last week, Digital World Acquisition's shares rose by as much as 1,500%. Mergers and acquisitions have been the name of the game for biotech investors this year.
Ocugen's share price has skyrocketed roughly seven times more than Novavax's has. Does that make Ocugen the smarter vaccine stock to buy right now? Here are seven reasons why Novavax stock is a no-brainer pick over Ocugen.